JP2017212998A5 - - Google Patents

Download PDF

Info

Publication number
JP2017212998A5
JP2017212998A5 JP2017136828A JP2017136828A JP2017212998A5 JP 2017212998 A5 JP2017212998 A5 JP 2017212998A5 JP 2017136828 A JP2017136828 A JP 2017136828A JP 2017136828 A JP2017136828 A JP 2017136828A JP 2017212998 A5 JP2017212998 A5 JP 2017212998A5
Authority
JP
Japan
Prior art keywords
seq
group
nos
sequence selected
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017136828A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017212998A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017212998A publication Critical patent/JP2017212998A/ja
Publication of JP2017212998A5 publication Critical patent/JP2017212998A5/ja
Withdrawn legal-status Critical Current

Links

JP2017136828A 2011-07-15 2017-07-13 転写活性化因子様エフェクターの組立て方法 Withdrawn JP2017212998A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161508366P 2011-07-15 2011-07-15
US61/508,366 2011-07-15
US201261601409P 2012-02-21 2012-02-21
US61/601,409 2012-02-21
US201261610212P 2012-03-13 2012-03-13
US61/610,212 2012-03-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014520317A Division JP6214530B2 (ja) 2011-07-15 2012-07-12 転写活性化因子様エフェクターの組立て方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019043522A Division JP2019122392A (ja) 2011-07-15 2019-03-11 転写活性化因子様エフェクターの組立て方法

Publications (2)

Publication Number Publication Date
JP2017212998A JP2017212998A (ja) 2017-12-07
JP2017212998A5 true JP2017212998A5 (cg-RX-API-DMAC7.html) 2018-03-15

Family

ID=47558397

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014520317A Active JP6214530B2 (ja) 2011-07-15 2012-07-12 転写活性化因子様エフェクターの組立て方法
JP2017136828A Withdrawn JP2017212998A (ja) 2011-07-15 2017-07-13 転写活性化因子様エフェクターの組立て方法
JP2019043522A Pending JP2019122392A (ja) 2011-07-15 2019-03-11 転写活性化因子様エフェクターの組立て方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014520317A Active JP6214530B2 (ja) 2011-07-15 2012-07-12 転写活性化因子様エフェクターの組立て方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019043522A Pending JP2019122392A (ja) 2011-07-15 2019-03-11 転写活性化因子様エフェクターの組立て方法

Country Status (6)

Country Link
US (3) US20140274812A1 (cg-RX-API-DMAC7.html)
EP (2) EP3461896B1 (cg-RX-API-DMAC7.html)
JP (3) JP6214530B2 (cg-RX-API-DMAC7.html)
AU (3) AU2012284365B2 (cg-RX-API-DMAC7.html)
CA (1) CA2841710C (cg-RX-API-DMAC7.html)
WO (1) WO2013012674A1 (cg-RX-API-DMAC7.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140274812A1 (en) 2011-07-15 2014-09-18 The General Hospital Corporation Methods of Transcription Activator Like Effector Assembly
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
WO2013017950A1 (en) * 2011-07-29 2013-02-07 Cellectis High throughput method for assembly and cloning polynucleotides comprising highly similar polynucleotidic modules
US9890364B2 (en) 2012-05-29 2018-02-13 The General Hospital Corporation TAL-Tet1 fusion proteins and methods of use thereof
EP3789405A1 (en) 2012-10-12 2021-03-10 The General Hospital Corporation Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
CA2900338C (en) 2013-02-07 2024-11-05 The General Hospital Corporation TRANSCRIPTIONAL ACTIVATORS TALE
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
KR102271292B1 (ko) 2013-03-15 2021-07-02 더 제너럴 하스피탈 코포레이션 Rna-안내 게놈 편집의 특이성을 증가시키기 위한 rna-안내 foki 뉴클레아제(rfn)의 용도
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
CN103789840A (zh) * 2014-02-07 2014-05-14 赛业(广州)生物科技有限公司 一种tale聚体库的构建方法
EP3957735A1 (en) 2014-03-05 2022-02-23 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
US11339437B2 (en) 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
EP3116997B1 (en) 2014-03-10 2019-05-15 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
US11141493B2 (en) 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
WO2015148863A2 (en) 2014-03-26 2015-10-01 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease
EP3540061A1 (en) 2014-04-02 2019-09-18 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating primary open angle glaucoma
WO2015153889A2 (en) * 2014-04-02 2015-10-08 University Of Florida Research Foundation, Incorporated Materials and methods for the treatment of latent viral infection
US20170088819A1 (en) * 2014-05-16 2017-03-30 Vrije Universiteit Brussel Genetic correction of myotonic dystrophy type 1
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
EP4019975A1 (en) 2015-04-24 2022-06-29 Editas Medicine, Inc. Evaluation of cas9 molecule/guide rna molecule complexes
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9840542B2 (en) * 2015-09-11 2017-12-12 Nomadogen Biotechnologies Inc. Methods and compositions for the packaging of nucleic acids into microglial exosomes for the targeted expression of polypeptides in neural cells
SG10202104041PA (en) 2015-10-23 2021-06-29 Harvard College Nucleobase editors and uses thereof
US11512311B2 (en) 2016-03-25 2022-11-29 Editas Medicine, Inc. Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency
US11566263B2 (en) 2016-08-02 2023-01-31 Editas Medicine, Inc. Compositions and methods for treating CEP290 associated disease
KR102827276B1 (ko) 2016-08-03 2025-07-01 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
CN110214180A (zh) 2016-10-14 2019-09-06 哈佛大学的校长及成员们 核碱基编辑器的aav递送
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
JP2020510038A (ja) 2017-03-09 2020-04-02 プレジデント アンド フェローズ オブ ハーバード カレッジ がんワクチン
KR20190127797A (ko) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 시토신에서 구아닌으로의 염기 편집제
WO2018170184A1 (en) 2017-03-14 2018-09-20 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
GB2575930A (en) 2017-03-23 2020-01-29 Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
EP3622070A2 (en) 2017-05-10 2020-03-18 Editas Medicine, Inc. Crispr/rna-guided nuclease systems and methods
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
EP3724214A4 (en) 2017-12-15 2021-09-01 The Broad Institute Inc. SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING
ES2993016T3 (en) * 2018-01-12 2024-12-20 Camena Bioscience Ltd Method for template-free geometric enzymatic nucleic acid synthesis
US20200405884A1 (en) * 2018-03-09 2020-12-31 Board Of Regents, The University Of Texas System Crispr-nanoparticles and methods of use in brain disorders
SG11202008956XA (en) 2018-03-14 2020-10-29 Editas Medicine Inc Systems and methods for the treatment of hemoglobinopathies
US12312383B2 (en) 2018-04-18 2025-05-27 Altius Institute For Biomedical Sciences Animal pathogen-derived polypeptides and uses thereof for genetic engineering
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
WO2020006126A1 (en) 2018-06-27 2020-01-02 Altius Institute For Biomedical Sciences Nucleic acid binding domains and methods of use thereof
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
DE112020001306T5 (de) 2019-03-19 2022-01-27 Massachusetts Institute Of Technology Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
AU2021267940A1 (en) 2020-05-08 2022-12-08 President And Fellows Of Harvard College Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US6900306B2 (en) 2001-08-01 2005-05-31 Isis Pharmaceuticals, Inc. Antisense modulation of CoREST expression
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
CA2131630A1 (en) 1992-03-10 1993-09-30 Yury E. Khudyakov Exchangeable template reaction
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
CN1127527A (zh) 1993-05-17 1996-07-24 加利福尼亚大学董事会 人免疫缺陷型病毒感染和艾滋病的核酶基因治疗方法
EP0722331A4 (en) 1993-08-25 1997-10-01 Systemix Inc METHOD FOR PRODUCING A POPULATION OF HIGHLY ENRICHED HEMATOPOIETIC STEM CELLS
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
USRE45721E1 (en) 1994-08-20 2015-10-06 Gendaq, Ltd. Relating to binding proteins for recognition of DNA
GB9618544D0 (en) 1996-09-05 1996-10-16 Brax Genomics Ltd Characterising DNA
US6335195B1 (en) 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US6440734B1 (en) 1998-09-25 2002-08-27 Cytomatrix, Llc Methods and devices for the long-term culture of hematopoietic progenitor cells
DE19812103A1 (de) 1998-03-19 1999-09-23 Bernauer Annette Verfahren zur Synthese von Nucleinsäuremolekülen
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6503717B2 (en) 1999-12-06 2003-01-07 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US8137906B2 (en) * 1999-06-07 2012-03-20 Sloning Biotechnology Gmbh Method for the synthesis of DNA fragments
DE19925862A1 (de) 1999-06-07 2000-12-14 Diavir Gmbh Verfahren zur Synthese von DNA-Fragmenten
US20020164575A1 (en) 1999-09-14 2002-11-07 Sangamo Biosciences, Inc., A Delaware Corporation Gene identification
AU2001226935B2 (en) 2000-01-24 2006-06-22 Gendaq Limited Nucleic acid binding polypeptides characterized by flexible linkers connected nucleic acid binding modules
AU2001257331A1 (en) 2000-04-28 2001-11-12 Sangamo Biosciences, Inc. Methods for designing exogenous regulatory molecules
JP2003531616A (ja) 2000-04-28 2003-10-28 サンガモ バイオサイエンシーズ, インコーポレイテッド 細胞性クロマチンに外因性分子を結合させるための方法
US7217509B2 (en) 2000-04-28 2007-05-15 Sangamo Biosciences, Inc. Databases of regulatory sequences; methods of making and using same
ATE353361T1 (de) 2000-04-28 2007-02-15 Sangamo Biosciences Inc Gezielten modifikation der chromatinstruktur
US7029847B2 (en) 2000-05-16 2006-04-18 Massachusetts Institute Of Technology Methods and compositions for interaction trap assays
US6492117B1 (en) 2000-07-12 2002-12-10 Gendaq Limited Zinc finger polypeptides capable of binding DNA quadruplexes
US6667064B2 (en) 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
JP2002262870A (ja) * 2000-11-09 2002-09-17 Nara Institute Of Science & Technology 固相において二本鎖dna分子を順次連結する方法およびその装置
WO2002057308A2 (en) 2001-01-22 2002-07-25 Sangamo Biosciences, Inc. Zinc finger polypeptides and their use
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
WO2004099366A2 (en) 2002-10-23 2004-11-18 The General Hospital Corporation Context sensitive parallel optimization of zinc finger dna binding domains
US7198165B2 (en) 2004-05-20 2007-04-03 Graham Packaging Pet Technologies Inc. Molded plastic hot-fill container and method of manufacture
US7741086B2 (en) 2004-12-16 2010-06-22 President And Fellows Of Harvard College Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
JP5078901B2 (ja) 2005-10-28 2012-11-21 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル JmjCドメインを含むタンパク質デメチラーゼ
GB0607063D0 (en) 2006-04-07 2006-05-17 Cellcentric Ltd Compositions and methods for epigenetic modification of nucleic acid sequences in vivo
CA2651494C (en) 2006-05-25 2015-09-29 Sangamo Biosciences, Inc. Engineered cleavage half-domains
CN101815722B (zh) 2007-09-28 2015-11-25 双刃基金会 Bs3抗性基因和使用方法
US20110112040A1 (en) 2008-04-28 2011-05-12 President And Fellows Of Harvard College Supercharged proteins for cell penetration
CN102027118B (zh) 2008-04-30 2014-07-30 桑比欧公司 含有dna甲基化状态改变的神经再生细胞
WO2010037001A2 (en) 2008-09-26 2010-04-01 Immune Disease Institute, Inc. Selective oxidation of 5-methylcytosine by tet-family proteins
WO2010054348A2 (en) 2008-11-10 2010-05-14 Two Blades Foundation Pathogen-inducible promoters and their use in enhancing the disease resistance of plants
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
WO2010129023A2 (en) 2009-04-28 2010-11-11 President And Fellows Of Harvard College Supercharged proteins for cell penetration
US20120178647A1 (en) * 2009-08-03 2012-07-12 The General Hospital Corporation Engineering of zinc finger arrays by context-dependent assembly
CA2770312A1 (en) 2009-08-11 2011-02-17 Sangamo Biosciences, Inc. Organisms homozygous for targeted modification
US8889394B2 (en) 2009-09-07 2014-11-18 Empire Technology Development Llc Multiple domain proteins
HUE041436T2 (hu) * 2009-12-10 2019-05-28 Univ Minnesota Tal-effektor-közvetített DNS-módosítás
AU2011213242B2 (en) 2010-02-08 2015-01-29 Sangamo Therapeutics, Inc. Engineered cleavage half-domains
WO2011146121A1 (en) 2010-05-17 2011-11-24 Sangamo Biosciences, Inc. Novel dna-binding proteins and uses thereof
CN103608027B (zh) * 2011-04-05 2016-01-20 赛莱蒂克斯公司 用于生成致密tale-核酸酶的方法及其用途
US20140274812A1 (en) 2011-07-15 2014-09-18 The General Hospital Corporation Methods of Transcription Activator Like Effector Assembly
WO2013017950A1 (en) * 2011-07-29 2013-02-07 Cellectis High throughput method for assembly and cloning polynucleotides comprising highly similar polynucleotidic modules
US9890364B2 (en) 2012-05-29 2018-02-13 The General Hospital Corporation TAL-Tet1 fusion proteins and methods of use thereof
EP3808844A1 (en) 2012-07-25 2021-04-21 The Broad Institute, Inc. Inducible dna binding proteins and genome perturbation tools and applications thereof
EP3789405A1 (en) 2012-10-12 2021-03-10 The General Hospital Corporation Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
CA2900338C (en) 2013-02-07 2024-11-05 The General Hospital Corporation TRANSCRIPTIONAL ACTIVATORS TALE
KR102271292B1 (ko) 2013-03-15 2021-07-02 더 제너럴 하스피탈 코포레이션 Rna-안내 게놈 편집의 특이성을 증가시키기 위한 rna-안내 foki 뉴클레아제(rfn)의 용도

Similar Documents

Publication Publication Date Title
JP2017212998A5 (cg-RX-API-DMAC7.html)
JP2019122392A5 (cg-RX-API-DMAC7.html)
JP2016034981A5 (cg-RX-API-DMAC7.html)
AR067023A1 (es) Polinucleotidos y metodos para obtener plantas resistentes a patogenos fungicos
JP2018520997A5 (cg-RX-API-DMAC7.html)
RU2017134456A (ru) Рекомбинантные связывающие белки и их применение
JP2017505117A5 (cg-RX-API-DMAC7.html)
NZ612405A (en) Nucleic acid molecules that target the vacuolar atpase c subunit and confer resistance to coleopteran pests
JP2009540801A5 (cg-RX-API-DMAC7.html)
CN109937252A (zh) 重组dna聚合酶
JP2016104790A5 (cg-RX-API-DMAC7.html)
JP2021505201A5 (cg-RX-API-DMAC7.html)
JP2010088434A5 (cg-RX-API-DMAC7.html)
JP2019214579A5 (cg-RX-API-DMAC7.html)
JP2015128433A5 (cg-RX-API-DMAC7.html)
MX2021004714A (es) Proteina cas9 modificada, y uso de la misma.
JP2007075118A5 (cg-RX-API-DMAC7.html)
JP2019537445A5 (cg-RX-API-DMAC7.html)
HRP20200471T1 (hr) Tonoplastni protonsko/šećerni antiporterski proteini i njihova upotreba u povećavanju koncentracije saharoze u biljnom organu za skladištenje saharoze
RU2016148309A (ru) Хорошо переносимая и высокоспецифическая адаптированная рекомбиназа для рекомбинирования асимметричных участков-мишеней во множестве штаммов ретровирусов
HRP20241279T1 (hr) Pripravak koji sadrži probiotike koji prekomjerno eksprimiraju protein clpb za uporabu u liječenju pretilosti
JP2014193147A5 (cg-RX-API-DMAC7.html)
JP2018534946A5 (cg-RX-API-DMAC7.html)
JP2017529868A5 (cg-RX-API-DMAC7.html)
JP2015119721A5 (cg-RX-API-DMAC7.html)